MX2016001193A - Medicamento que comprende anticuerpo anti-fosfolipasa d4. - Google Patents
Medicamento que comprende anticuerpo anti-fosfolipasa d4.Info
- Publication number
- MX2016001193A MX2016001193A MX2016001193A MX2016001193A MX2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A MX 2016001193 A MX2016001193 A MX 2016001193A
- Authority
- MX
- Mexico
- Prior art keywords
- phospholipase
- present application
- pld4
- medicaments
- application provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente solicitud proporciona los medicamentos que comprenden los anticuerpos que se unen a la fosfolipasa D4 (PLD4) así como también un método que utiliza los medicamentos para detectar y suprimir células B activadas. La presente solicitud se dirige además a la terapia de enfermedades autoinmunes y alergosis, que resulta de una función de represión activa. Con el propósito de resolver esos problemas, la presente solicitud proporciona ese anticuerpo monoclonal que se une al dominio extracelular de la proteína de fosfolipasa D4 (PLD4), o un fragmento que contiene una región de unión a antígenos del mismo como un ingrediente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013158258 | 2013-07-30 | ||
| PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001193A true MX2016001193A (es) | 2016-05-26 |
Family
ID=51493000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001193A MX2016001193A (es) | 2013-07-30 | 2014-07-30 | Medicamento que comprende anticuerpo anti-fosfolipasa d4. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160168266A1 (es) |
| EP (1) | EP3027656B1 (es) |
| JP (3) | JP6431523B2 (es) |
| KR (1) | KR102367760B1 (es) |
| CN (1) | CN105745226B (es) |
| AU (1) | AU2014297217B2 (es) |
| BR (1) | BR112016002001B1 (es) |
| CA (1) | CA2919736C (es) |
| DK (1) | DK3027656T3 (es) |
| ES (1) | ES2736324T3 (es) |
| HU (1) | HUE044469T2 (es) |
| MX (1) | MX2016001193A (es) |
| PL (1) | PL3027656T3 (es) |
| RU (1) | RU2709741C2 (es) |
| SG (2) | SG11201600666SA (es) |
| TR (1) | TR201910330T4 (es) |
| WO (1) | WO2015016386A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3431504T3 (pl) * | 2012-01-31 | 2021-10-18 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| BR112019000544A2 (pt) * | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
| JP7140367B2 (ja) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | ヒト由来サンプルにおける可溶型ｔｌｒ７の分析 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE196606T1 (de) * | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| JP2002537757A (ja) * | 1998-08-24 | 2002-11-12 | アルファジーン・インコーポレイテッド | 分泌タンパク質及びそれらをコードするポリヌクレオチド |
| AU2002239505A1 (en) * | 2000-12-07 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
| JP2013052781A (ja) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | 車両用ミラー装置 |
| PL3431504T3 (pl) * | 2012-01-31 | 2021-10-18 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
-
2014
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/ru active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/tr unknown
- 2014-07-30 MX MX2016001193A patent/MX2016001193A/es unknown
- 2014-07-30 PL PL14761423T patent/PL3027656T3/pl unknown
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/hu unknown
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/zh active Active
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/da active
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/pt active IP Right Grant
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/ko active IP Right Grant
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en active Application Filing
- 2014-07-30 ES ES14761423T patent/ES2736324T3/es active Active
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/ja active Active
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/ja not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/ja active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160034934A (ko) | 2016-03-30 |
| AU2014297217A1 (en) | 2016-02-18 |
| TR201910330T4 (tr) | 2019-07-22 |
| KR102367760B1 (ko) | 2022-02-24 |
| CA2919736A1 (en) | 2015-02-05 |
| ES2736324T3 (es) | 2019-12-27 |
| EP3027656B1 (en) | 2019-06-26 |
| BR112016002001B1 (pt) | 2023-04-25 |
| JP6843449B2 (ja) | 2021-03-17 |
| DK3027656T3 (da) | 2019-08-05 |
| CN105745226B (zh) | 2020-03-06 |
| RU2016106708A (ru) | 2017-09-01 |
| CA2919736C (en) | 2022-03-22 |
| CN105745226A (zh) | 2016-07-06 |
| PL3027656T3 (pl) | 2019-10-31 |
| WO2015016386A1 (en) | 2015-02-05 |
| EP3027656A1 (en) | 2016-06-08 |
| JP2019014759A (ja) | 2019-01-31 |
| US20210130493A1 (en) | 2021-05-06 |
| HUE044469T2 (hu) | 2019-10-28 |
| JP6431523B2 (ja) | 2018-11-28 |
| JP2019214621A (ja) | 2019-12-19 |
| SG10201800592SA (en) | 2018-03-28 |
| RU2709741C2 (ru) | 2019-12-19 |
| RU2016106708A3 (es) | 2018-03-30 |
| JP2016534022A (ja) | 2016-11-04 |
| AU2014297217B2 (en) | 2020-01-16 |
| SG11201600666SA (en) | 2016-02-26 |
| BR112016002001A2 (pt) | 2017-08-29 |
| US20160168266A1 (en) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501120B1 (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| PH12015500196A1 (en) | Methods of treating a tauopathy | |
| PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
| EA201391564A1 (ru) | Полипептиды антитела, которые антагонизируют cd40 | |
| EA201300133A1 (ru) | Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ | |
| NZ709997A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| EA201690503A1 (ru) | Антитела | |
| IN2015KN00350A (es) | ||
| MX2019015604A (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia. | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| EA201991704A3 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA201300137A1 (ru) | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями | |
| BR112016002401A8 (pt) | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| EA201590359A1 (ru) | Лечение ревматоидного артрита | |
| WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| EA201590061A1 (ru) | Фармацевтическая композиция | |
| BR112016010336A2 (pt) | Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer | |
| MX2016001193A (es) | Medicamento que comprende anticuerpo anti-fosfolipasa d4. | |
| MX2018007925A (es) | Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo. | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof |